Previous 10 | Next 10 |
home / stock / azncf / azncf news
2023-11-02 09:00:00 ET Summary Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate. Pfizer's low Price-to-Earnings ratio and imp...
2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...
2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...
2023-10-15 07:15:00 ET Summary Suzhou MediLink Therapeutics out-licenses global rights for its HER3 antibody-drug conjugate candidate to BioNTech in a $1.1 billion deal. Beijing AI drug discovery company BioMap forms a strategic collaboration with Sanofi to co-develop new protein ...
2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...
2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...
2023-09-17 12:00:54 ET The impact of COVID, flu, and RSV on U.S. and U.K. hospitals is expected to be lower this winter compared to last, as there won't be a significant overlap between peak outbreaks of infections, the London-based data analytics firm Airfinity said in a recent report. ...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...